Search

Additional file 4. Scenario analyses.

Additional file 3. Model’s risk factor cut-off values and corresponding transition probabilities.

Additional file 1. Within trial data.

Additional file 2. Specification of cost data.

Additional file 1. Detailed overview of different response enhancing strategies. p.p. = per patient, min = minute(s), RS = risk score * Average practice size of 2095 patient, approximately 375 patients eligible for prevention program. ** If 19% of patients with increased risk on RS order the box (17 patients).

Table S3. Characteristics of non-responders at 6 or 12 months follow-up (n = 109). (DOCX 22 kb)

Table S1. CONSORT 2010 checklist for reporting a cluster randomised trial & Extension of CONSORT for abstracts to reports of cluster randomised trials. Table S2. Extension of CONSORT for abstracts to reports of cluster randomised trials. (DOCX 33 kb)

Univariate regression of high cardiovascular disease risk in men for sociodemographic, lifestyle and biometric variables. (DOC 106Â kb)

A method for manufacturing a single crystal nano-structure is provided comprising the steps of providing a device layer with a 100 structure on a substrate; providing a stress layer onto the device layer; patterning the stress layer along the 110 direction of the device layer; selectively removing parts of the stress layer to obtain exposed parts of the device layer; plane dependent etching of the exposed parts of the device layer to obtain an exposed 111 faces of the device layer; thermally oxidizing the exposed 111 face of the device layer and forming a lateral oxidation layer at an interface of the device layer and the stress layer; providing a mask layer onto the oxidized exposed 111 face of the device layer; removing remaining parts of the stress layer to obtain further exposed parts of the device layer; removing the mask layer; plane dependent etching of the further exposed parts of the device layer to form a single crystal nano-structurewith a triangular shaped cross section, until a side of the triangular shaped cross section coplanar to a side of a cross section of the oxidized exposed 111 face is small in comparison with said side of the cross section of the oxidized exposed 111 face

The invention relates to a capsule or chip or sensor comprising a marker/detector and signalling device/method associated with the development of a medical condition/disease and to its use. This In Situ Lab On a Chip Signalling device (ISLOGS device) is used for detecting a medical condition/disease in situ or in vivo (inside the body), for example by swallowing it for testing in the digestive tract or by putting it into the vagina, mouth or nose. All reactions takes place in the body and when the test result is positive the device will notify the subject by colorizing the tested body fluid or biomaterial (for example faeces, urine or saliva) or the device itself. The detection is made outside of the body when the biomaterial or ISLOCS device has left the body.